MARKET

EWTX

EWTX

Edgewise Therapeutics, Inc.
NASDAQ
40.63
-0.29
-0.71%
After Hours: 40.63 0 0.00% 18:49 06/30 EDT
OPEN
40.97
PREV CLOSE
40.92
HIGH
42.02
LOW
40.48
VOLUME
968.03K
TURNOVER
--
52 WEEK HIGH
43.93
52 WEEK LOW
12.30
MARKET CAP
4.37B
P/E (TTM)
-24.4656
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EWTX last week (0622-0626)?
Weekly Report · 1d ago
Why Edgewise Therapeutics (EWTX) Is Up 13.3% After Phase 2 EDG-7500 HCM Data Release
Simply Wall St · 4d ago
Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress
Simply Wall St · 06/22 15:24
Weekly Report: what happened at EWTX last week (0615-0619)?
Weekly Report · 06/22 09:38
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 06/18 14:31
How Positive CIRRUS-HCM Phase 2 Data and Preserved Systolic Function Will Impact Edgewise Therapeutics (EWTX) Investors
Simply Wall St · 06/17 21:26
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 06/17 15:12
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59
Benzinga · 06/17 15:02
More
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Webull offers Edgewise Therapeutics Inc stock information, including NASDAQ: EWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EWTX stock methods without spending real money on the virtual paper trading platform.